The impact of anti-rituximab antibodies on rituximab efficacy in children with frequently relapsing or steroid-dependent nephrotic syndrome

This study investigates the impact of anti-rituximab antibodies (ARA) on the efficacy of rituximab (RTX) in children with frequently relapsing or steroid-dependent nephrotic syndrome. The authors found that ARA positivity is associated with lower RTX serum levels, shorter B-cell depletion duration, and a higher risk of relapse, although it does not significantly affect treatment safety. The findings suggest that monitoring ARA status could help optimize RTX therapy in this pediatric population.